spacer
home > ebr > Summer 2016
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2016

   
Text
PDF
Editor’s Letter

EBR’s Editor Deborah O’Neil introduces July’s edition by highlighting the speed at which pharma is moving towards an age of biologics, while discussing the emerging possibility of earlier diagnosis for all patients.
 
view
download pdf
bullet
BioResearch and Innovation
Dementia Spotlight

How to Get a Pre-Competitive Edge


Rodrigo Barnes
at Aridhia discusses the possibility of unlocking the secrets of dementia to reduce its effect. With the costs of the disease – both economic and personal – on the rise, the time is right for a more collaborative approach to curing it.
 
view
download pdf
Liquid Biopsies

Translating Research into Reality: Part 1


As DNA sequencing looks increasingly towards the use of liquid biopsies, the industry moves ever-closer to developing personalised treatment for all patients. Paul Elvin at Aptus Clinical explains the need to target specific mutations, and the effect that new ctDNA analysis may have on patients and developers alike.
 
view
download pdf
BioDiscovery
Biomarkers and Diagnostics

The Secrets in our Cells


Diamond Light Source’s Mary Cruse
sheds light upon recent work undertaken in cancer research, and the prospect of tailoring treatment to the genetic codes of any given patient – stating that perhaps the successful cure lies in each individual’s chemistry.
 
view
download pdf
bullet
INDUSTRY DYNAMICS
Comment: Shipment Conditions

How Strong is a Peptide Bond?


Have you ever wondered how much you could save on your logistics costs? According to Dr Henk J Bak at Eurosequence, there is a simple solution: bidding farewell to outdated methods and adopting more relevant shipping procedures.
 
view
download pdf
In Brief

Less is More


Governments, payers and patients alike are all calling for businesses worldwide to “do more with less”. Emile Bellott looks at the challenges we face as demands placed on the healthcare system threaten to intensify.
 
view
download pdf
bullet
BUSINESS STRATEGY
Content Management Software

Curse of the Patchwork Monster


The transformation of the life sciences landscape due to the digital revolution has created a stronger, quicker supply chain process. However, John Chinnici at Veeva Systems explains that despite its benefits, paper-based processes are still used by many companies. This can be combatted by implementing a fully digitalised supply chain.
 
view
download pdf

eHealth Revolution

From the Outside


Innovation from external sources has the potential to revolutionise the biopharma industry. Dr Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré andDr Richard Beetz at Arthur D. Little suggest that by embracing the digital, a positive change could be created for patient care, even if it means advances in other areas lose pace.

 
view
download pdf
bullet
RESEARCH AND DEVELOPMENT
Q&A: Idiopathic Pulmonary Fibrosis

Breathing Easy


In our latest Q&A, Dr Marilyn Glassberg enlightens EBR on everything from the main themes raised at ATS 2016 to her recent research, before revealing her biggest lesson in life.
 
view
download pdf
bullet
BIOIMAGING
Two-Photon Microscopy

The Next Step


A plethora of options have emerged to improve imaging capabilities for microscopists. Laser Quantum’s Andrew Wells explains the change in the priorities of manufacturers of laser equipment, and discusses the benefits of using ultra-fast lasers.
 
view
download pdf
bullet
CELL-BASED RESEARCH
Cell Disruption

Under Pressure


Technology that performs mechanical lysis and homogenisation of cells are often sold on the basis of the pressure they are able to reach. Recent research undertaken by Dr Matthew Lougher of Constant Systems, however, demonstrates that the success of mechanical cell disruptions depends on much more than pressure.
 
view
download pdf
Cell Culture Development

Up to Speed


Research shows that reducing the development time and costs associated with cell culture processes can be achieved by instigating high-throughput methods. Shahid Rameez and Abhinav A Shukla at KBI Biopharma discuss what this means for progress in novel biotherapeutics and their use in clinical trials.
 
view
download pdf
bullet
THERAPEUTIC DEVELOPMENT
Biosimilar Manufacturing

Gaining Ground


ProductLife Group’s Barbara Testa highlights the fact that the biosimilar sector is wrought with challenges regarding patient satisfaction and understanding – she explains that biosimilar popularity continues to rise, but physicians remain tentative.
 
view
download pdf
Genetic Disorder Therapeutics

Two Pillars of Fledgling RNA Medicine


It is becoming progressively difficult to find efficient, predictable and safe intracellular delivery strategies for curing genetic disorders. With the hope that a fuller understanding of RNA therapies will accelerate the process, Max Ryadnov at the National Physical Laboratory outlines the two main obstacles facing researchers and developers.
 
view
download pdf
Developments in Biosimilars

Winning the Race


The biosimilar testing process is complex, but it is becoming increasingly possible to employ a successful development programme. Dr Jon S Kauffman, Dr Weihong Wang and Dr Frederic Girard at Eurofins explore the feasibility of implementing these methods across the biopharma sector.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Saneca to drive R&D Initiative following €1.5 million funding


More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

Industry Events

BIO-Europe® 2017

6-8 November 2017, Messedamm 26 14055 Berlin Germany

The 23rd annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 3,800 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement